Velsipity™

INN: etrasimod

Approved for use in:

Ulcerative Colitis (moderate-severe)

Type/Class

Oral Small Molecule (S1P-receptor modulator)

Delivery Route

Oral (tablet)

Health Canada Approval

2024

Storage

Store between 15 and 25°C.

Use in Older Adults (65+)

May be used, please consult your doctor.

Pregnancy Indication

Can cause fetal harm; women of reproductive potential should be advised to use contraception during treatment and for at least 6 days afterwards.

Breastfeeding Indication

Not recommended.

Pediatric Indication

Not authorized.

Learn More

View the Velsipity™ product monograph.